China Pharma Holdings Inc (CPHI)vsUnited Therapeutics Corporation (UTHR)
CPHI
China Pharma Holdings Inc
$0.72
-12.90%
HEALTHCARE · Cap: $32.77M
UTHR
United Therapeutics Corporation
$549.87
+0.40%
HEALTHCARE · Cap: $23.17B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 76386% more annual revenue ($3.17B vs $4.14M). UTHR leads profitability with a 40.6% profit margin vs -76.9%. CPHI appears more attractively valued with a PEG of 0.16. UTHR earns a higher WallStSmart Score of 57/100 (C).
CPHI
Avoid35
out of 100
Grade: F
UTHR
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+42.9%
Fair Value
$1.10
Current Price
$0.72
$0.38 discount
Margin of Safety
+2.5%
Fair Value
$487.82
Current Price
$549.87
$62.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Conservative balance sheet, low leverage
Keeps 41 of every $100 in revenue as profit
Strong operational efficiency at 41.7%
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -20.9% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Revenue declined 1.6%
Earnings declined 12.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : CPHI
The strongest argument for CPHI centers on PEG Ratio, Price/Book, Debt/Equity. PEG of 0.16 suggests the stock is reasonably priced for its growth.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 40.6% and operating margin at 41.7%.
Bear Case : CPHI
The primary concerns for CPHI are EPS Growth, Market Cap, Return on Equity.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
CPHI profiles as a turnaround stock while UTHR is a declining play — different risk/reward profiles.
CPHI carries more volatility with a beta of 1.00 — expect wider price swings.
CPHI is growing revenue faster at 8.1% — sustainability is the question.
UTHR generates stronger free cash flow (363M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (57/100 vs 35/100), backed by strong 40.6% margins. CPHI offers better value entry with a 42.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
China Pharma Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · China
China Pharma Holdings, Inc. develops, manufactures and markets generic and branded pharmaceutical and biochemical products primarily for hospitals and private retailers in the People's Republic of China. The company is headquartered in Haikou, the People's Republic of China.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?